Abstract:We performed an ab initio next-generation risk assessment (NGRA) for a fragrance ingredient, benzyl salicylate (BSal), to demonstrate how cosmetic ingredients can be evaluated for systemic toxicity endpoints based on non-animal approaches. New approach methodologies (NAMs) used to predict the internal exposure included skin absorption assays, hepatocyte metabolism, and physiologically based pharmacokinetic (PBPK) modeling, and potential toxicodynamic effects were assessed using pharmacology profiling, ToxProfiler cell stress assay, transcriptomics in HepG2 and MCF-7 cells, ReproTracker developmental and reproductive toxicology (DART) assays, and cytotoxicity assays in human kidney cells. The outcome of the NGRA was compared to that of the traditional risk assessment approach based on animal data. The identification of the toxicologically critical entity was a critical step that directed the workflow and the selection of chemicals for PBPK modeling and testing in bioassays. The traditional risk assessment and NGRA identified salicylic acid (SA) as the "toxdriver." A deterministic PBPK model for a single-day application of 1.54 g face cream containing 0.5% BSal estimated the C max for BSal (1 nM) to be much lower than that of its major in vitro metabolite, SA (93.2 nM). Therefore, SA was tested using toxicodynamics bioassays. The lowest points of departure (PoDs) were obtained from the toxicogenomics assays. The interpretation of these results by two companies and methods were similar (SA only results in significant gene deregulation in HepG2 cells), but PoD differed (213 μM and 10.6 μM). A probabilistic PBPK model for repeated applications of the face cream estimated the highest C max of SA to be 630 nM. The resulting margins of internal exposure (MoIE) using the PoDs were 338 and 16, which were more conservative than those derived from external exposure and in vivo PoDs (margin of safety values were 9,705). In conclusion, both traditional and ab initio NGRA approaches concluded that the daily application of BSal in a cosmetic leave-on face cream at 0.5% is safe for humans. The processing and interpretation of toxicogenomics data can lead to different PoDs, which can subsequently affect the calculation of the MoIE. This case study supports the use of NAMs in a tiered NGRA ab initio approach.

GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) framework

In Vitro Prediction of Skin-Sensitizing Potency Using the GARDskin Dose–Response Assay: A Simple Regression Approach

Validation of the GARD™skin Assay for Assessment of Chemical Skin Sensitizers: Ring Trial Results of Predictive Performance and Reproducibility

Predicting points of departure and potency categories for fragrance ingredients by integrating OECD in vitro models

Next generation risk assessment: an ab initio case study to assess the systemic safety of the cosmetic ingredient, benzyl salicylate, after dermal exposure

Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients

Deriving a Continuous Point of Departure for Skin Sensitization Risk Assessment Using a Bayesian Network Model

Deriving a Point of Departure for Assessing the Skin Sensitization Risk of Wearable Device Constituents with In Vitro Methods

Results of patch testing with five fragrance materials hitherto not tested: A dose‐finding study in the clinical population

Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment

Skin Sensitisation Case Study: Comparison of Defined Approaches including OECD 497 Guidance

Skin Sensitization Potency Prediction Based on Read‐Across (RAx) Incorporating RhE‐Based Testing Strategy (RTSv1)–Defined Approach: RTSv1‐Based RAx

Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the "2 out of 3" Defined Approach

Quantum-Mechanics Calculations Elucidate Skin-Sensitizing Pharmaceutical Compounds

Development of a peptide reactivity assay for screening botanicals and natural substances: Proof of concept studies

In Vitro Dendritic Cell-Based Test for Skin Sensitizers Identification and Potency Estimation

Limitations and Modifications of Skin Sensitization NAMs for Testing Inorganic Nanomaterials

Nano(Q)SAR: Challenges, Pitfalls and Perspectives

Increasing Accessibility of Bayesian Network-Based Defined Approaches for Skin Sensitisation Potency Assessment

Human relevance of in vivo and in vitro skin irritation tests for hazard classification of pesticides

Computational application of internationally harmonized defined approaches to skin sensitization: DASS App